Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

M&T Bank Corp lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 10.0% in the 4th ...

Golf, often a game of patience and calculated risks, has a way of humbling even the greatest players. Just when it seems like ...

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Rio Takeda shot a blistering 8-under 64 to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia.

Rio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Rio Takeda shot a blistering 8-under 64 to win the LPGA's Blue Bay tournament by six shots ahead of Minjee Lee.

SANYA, China — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA’s Blue Bay tournament by six shots ahead of ...